SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Akero Therapeutics, Inc. (AKRO) , forward earnings yield 1.46%.
Criteria proven by this page:
- VALUE (20/100, Fail) — analyst consensus target implies downside from the current price ($46.00, 15.8%).
- Forward P/E 68.3
- Analyst consensus target $46.00 (-15.8% downside) — analysts see meaningful downside risk at the current price level.
Overall SharesGrow Score: 36/100 with 1/7 criteria passed.
SharesGrow 7-Criteria Score
✗
VALUE
20/100
Price-to-Earnings & upside
Proven by this page
✓
HEALTH
100/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — AKRO
Valuation Multiples
P/E (TTM)0.0
Forward P/E68.3
PEG RatioN/A
Forward PEGN/A
P/B Ratio0.00
P/S Ratio0.00
EV/EBITDA0.0
Per Share Data
EPS (TTM)$-3.75
Forward EPS (Est.)$0.80
Book Value / Share$0.00
Revenue / Share$0.00
FCF / Share$0.00
Yields & Fair Value
Earnings YieldN/A
Forward Earnings Yield1.46%
Dividend Yield0.00%
Analyst Target$46.00 (-15.8%)
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2017 |
$-0.16 |
$0.00 |
$-4.56M |
- |
| 2018 |
$-3.85 |
$0.00 |
$-81.71M |
- |
| 2019 |
$-2.90 |
$0.00 |
$-43.76M |
- |
| 2020 |
$-2.52 |
$0.00 |
$-79.19M |
- |
| 2021 |
$-2.89 |
$0.00 |
$-100.74M |
- |
| 2022 |
$-2.79 |
$0.00 |
$-108.91M |
- |
| 2023 |
$-2.89 |
$0.00 |
$-151.76M |
- |
| 2024 |
$-3.75 |
$0.00 |
$-252.06M |
- |
